Feasibility and usefulness of symptom monitoring with electronic patient-reported outcomes: an experience at single-center outpatient oncology clinic.

Autor: Kurosawa S; Department of Oncology, Ina Central Hospital, 1313-1 Koshiro-Kubo, Ina, Nagano, 396-8555, Japan. skurosaw@inahp.jp., Koike K; Nursing Division, Ina Central Hospital, Ina, Japan., Arai T; Nursing Division, Ina Central Hospital, Ina, Japan., Yoshida S; Nursing Division, Ina Central Hospital, Ina, Japan., Ito M; Nursing Division, Ina Central Hospital, Ina, Japan., Kuriyama Y; Nursing Division, Ina Central Hospital, Ina, Japan., Kitahara M; Pharmaceutical Division, Ina Central Hospital, Ina, Japan., Rokuhara T; Pharmaceutical Division, Ina Central Hospital, Ina, Japan., Yamaguchi T; Division of Biostatistics, Tohoku University Graduate School of Medicine, Sendai, Japan., Takeuchi N; Department of Oncology, Ina Central Hospital, 1313-1 Koshiro-Kubo, Ina, Nagano, 396-8555, Japan.
Jazyk: angličtina
Zdroj: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer [Support Care Cancer] 2024 Dec 04; Vol. 33 (1), pp. 3. Date of Electronic Publication: 2024 Dec 04.
DOI: 10.1007/s00520-024-09062-5
Abstrakt: Purpose: The benefit of patient-reported outcomes (PRO) in routine oncology practice is increasingly recognized. This study aimed to develop a team-based monitoring and intervention system using electronic PRO (ePRO) and to evaluate its impact at an outpatient oncology clinic.
Methods: Patients receiving chemotherapy at our department were eligible for this study. Those who had access to a smartphone or tablet (Bring Your Own Device [BYOD]) and consented participated, and reported 28 symptoms weekly via 3H P-guardian downloaded on their BYOD. E-mail alerts were sent to attending healthcare providers when participants reported at least grade 3 severity for any of nine symptoms (decreased appetite, nausea, vomiting, diarrhea, shortness of breath, pain, insomnia, fatigue, and sadness), which prompted interventions. Comparisons of overall survival (OS), emergency room visits, and hospitalizations were conducted using propensity scores.
Results: Among 203 patients who received chemotherapy from September 2021 to August 2023, 77 participated in ePRO monitoring. The overall response rate was 55% (1991 valid responses out of a total of 3597 expected time points), and the median individual response rate was 66% (range, 0-100%). Of 1991 valid responses, 250 (13%) prompted alerts, and most interventions were initiated by making telephone calls. OS and other clinical outcomes were better in ePRO participants compared with non-participants, but these outcomes did not differ significantly between the ePRO and pre-ePRO eras.
Conclusions: It was feasible to develop a multi-professional team-based monitoring and intervention system using ePRO at a single-center outpatient oncology clinic. Our results indicate that weekly monitoring of ePRO, along with corresponding interventions, may benefit patients receiving chemotherapy.
Competing Interests: Declarations. Ethics approval: The protocol was approved by the institutional review board of Ina Central Hospital. Consent to participate: All subjects provided informed consent in accordance with the Declaration of Helsinki. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.
(© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
Databáze: MEDLINE
Externí odkaz: